InspireMD Inc (NYSEAMERICAN: NSPR) is having an incredibly strong start to the trading session this morning, and for good reason. The company announced the presentation of clinical data, exciting investors and sending the stock screaming for the top. Today, we’ll talk about:
- The data;
- what we’re seeing from NSPR as a result; and
- what we’ll be watching for ahead.
NSPR Announces Presentation Of Data
As mentioned above, InspireMD is having a great start to the trading session this morning after announcing the presentation of data. In a press release issued early this morning, the company announced that preliminary cumulative three-year follow-up safety, efficacy and stroke prevention durability data from the PARADIGM-Extend trial of CGuard™ EPS was presented at the Cardiovascular Research Foundation’s Transcatheter Cardiovascular Therapeutics (TCT) 2018 conference, which was held September 21-25 in San Diego.
In the release, NSPR said that overall cumulative data showed no stroke or stroke-related deaths between 24 and 36 months. The data was also absent of any device related issues in the first 93 of 251 patients in the PARADIGM-Extend cohort. In a statement, James Barry, PhD, CEO at NSPR, had the following to offer:
We are grateful to Prof. Musiałek for his continued interest in CGuard™ EPS for treating all his patients with carotid artery disease, and we are pleased that the data from this investigator-led study continues to demonstrate strong safety and efficacy up to 36 months post-procedure… With this latest presentation, we are compiling a significant body of evidence suggesting that treatment with CGuard™ EPS could result in sustained, long term normal vessel healing with no device-related issues. We look forward to the presentation of additional three-year data at the 45th Annual Symposium on Vascular and Endovascular Issues, Techniques, Horizons (VEITHsymposium) in New York in November.
What We’re Seeing From The Stock
One of the first lessons that we learn when we start to work in the market is that the news leads to moves. In the case of InspireMD, the news proved to be ovewhelmingly positive. The new preliminary data suggest that the treatment is effective and likely safe and well-tolerated. So, it comes as no surprise to see that excited investors are sending the stock screaming for the top. As is normally the case, our partners at Trade Ideas were the first to alert us to the gains. Currently (10:37), NSPR is trading at $0.24 per share after a gain of $0.02 per share or 9.20% thus far today.
Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!
What We’ll Be Watching For Ahead
Moving forward, the CNA Finance team will continue to keep a close eye on NSPR. In particular, we’re interested in following the news surrounding the company’s CGurad EPS system as the candidate is generating solid data. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!
Never Miss The News Again
Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!